Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HNC042 Phase 1 SAD/MAD in Healthy Subjects
NCT03740555Phase 1Completed
- Sponsor
- Guangzhou Henovcom Bioscience Co., Ltd.
- Start
- Nov 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HNC042 in influenza (4 arms), sponsored by Guangzhou Henovcom Bioscience Co., Ltd. Primary endpoints: Number of subjects with adverse events, Number of subjects with abnormal laboratory and 3 more. Started Nov 2018; status: completed.
02
Drugs
HNC042
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03740555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03740555.